Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this study, the safety, tolerability and activity of CLT-008 administered after "standard of care" cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD), neutrophil and platelet recovery, hMPC persistence, infections and complications.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cellerant Therapeutics
• Collaborator: Department of Health and Human Services
• Treatments: Cytarabine; Lenograstim; Sargramostim

Criteria

Key Inclusion Criteria:

• Hematological malignancy, including:

• AML, ALL or MDS

• Planned treatment with cytarabine-based chemotherapy regimen

• Adequate hepatic, renal, hematologic, cardiac and respiratory function

Key Exclusion Criteria:

• Prior allograft or history of active GVHD within 3 years

• Pregnant or nursing